Vanbrugghe C, Bartoli M A, Ouaissi M, Sarlon G, Amabile P, Magnan P-É, Soler R J
Vascular surgery department, CHU de Timone, 264, rue Saint-Pierre, 13385 Marseille, France; General and visceral surgery departement, hôpital Nord, chemin des Bourrely, 13015 Marseille, France.
Vascular surgery department, CHU de Timone, 264, rue Saint-Pierre, 13385 Marseille, France.
J Med Vasc. 2020 Jul;45(4):177-183. doi: 10.1016/j.jdmv.2020.04.009. Epub 2020 May 5.
To evaluate the short and long-term results of in situ prosthetic graft treatment using rifampicin-soaked silver polyester graft in patients with aortic infection.
All the patients surgically managed in our center for an aortic infection were retrospectively analyzed. The primary endpoint was the intra-hospital mortality, secondary outcomes were limb salvage, persistent or recurrent infection, prosthetic graft patency, and long-term survival.
From January 2004 to December 2015, 18 consecutive patients (12 men and 6 women) were operated on for aortic infection. Six mycotic aneurysms and 12 prosthetic infections, including 8 para-entero-prosthetic fistulas, were treated. In 5 cases, surgery was performed in emergency. During the early postoperative period, we performed one major amputation and two aortic infections were persistent. Intra-hospital mortality was 27.7%. The median follow-up among the 13 surviving patients was 26 months. During follow-up, none of the 13 patients presented reinfection or bypass thrombosis.
This series shows that in situ revascularization with rifampicin-soaked silver polyester graft for aortic infection have results in agreement with the literature in terms of intra-hospital mortality with a low reinfection rate.
评估使用利福平浸泡的银聚酯移植物进行原位人工血管移植治疗主动脉感染患者的短期和长期结果。
对在我们中心接受手术治疗的所有主动脉感染患者进行回顾性分析。主要终点是院内死亡率,次要结局是肢体保全、持续性或复发性感染、人工血管通畅率和长期生存率。
2004年1月至2015年12月,连续18例患者(12例男性和6例女性)接受了主动脉感染手术。治疗了6例真菌性动脉瘤和12例人工血管感染,其中包括8例肠旁人工血管瘘。5例患者进行了急诊手术。术后早期,我们进行了1例大截肢手术,2例主动脉感染持续存在。院内死亡率为27.7%。13例存活患者的中位随访时间为26个月。随访期间,13例患者均未出现再次感染或旁路血栓形成。
本系列研究表明,使用利福平浸泡的银聚酯移植物进行主动脉感染的原位血管重建,在院内死亡率方面与文献结果一致,再感染率较低。